News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Galectin Therapeutics Announces Research Collaboration with Dr. Jose Jalife of the University of Michigan Medical School to Explore Role of Galectins in Cardiovascular Disease



7/21/2011 8:07:55 AM

NEWTON, Mass.--(BUSINESS WIRE)--Galectin Therapeutics Inc. (OTC: GALT) today announced that it has entered into a research collaboration with Dr. Jose Jalife of the University of Michigan Medical School to better understand the relationship of Galectin-3 to cardiac fibrosis in chronic cardiac arrhythmias. Galectin-3 is known to be increased in patients with heart failure and is believed to be a critical mediator in the development of cardiac fibrosis. Understanding of these mechanisms could ultimately lead to new therapeutic approaches, including galectin inhibition, to cardiac fibrosis and chronic arrhythmias.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES